Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager
January 7, 2025
Candid Therapeutics, a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases, announced an agreement with WuXi